Form 8-K - Current report:
SEC Accession No. 0000950170-24-138563
Filing Date
2024-12-19
Accepted
2024-12-19 17:07:26
Documents
13
Period of Report
2024-12-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pyxs-20241219.htm   iXBRL 8-K 46209
2 EX-99.1 pyxs-ex99_1.htm EX-99.1 28735
3 GRAPHIC img244827169_0.jpg GRAPHIC 46807
  Complete submission text file 0000950170-24-138563.txt   260784

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20241219.xsd EX-101.SCH 25999
15 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20241219_htm.xml XML 4912
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40881 | Film No.: 241564124
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)